Associated Papers
HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities.
Ismail A et al.
Frontiers in Oncology, 2025
Plasma-based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer.
Corné J et al.
Molecular Oncology, 2024
Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects.
Ishiyama N et al.
Cancer Research, 2023
35503682 (PubMed )
Supplement: can-21-0940_supplementary_data_suppsd.docx
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
37168365 (PubMed )
Supplement: Table_4.xlsx › ERBB2_mutations
Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer.
Kalra R et al.
Cancer Research, 2022
35736563 (PubMed )
Supplement: can-21-3106_supplementary_data_suppst1.xlsx › METABRIC
Targeting HER2 genomic alterations in non-small cell lung cancer.
Zeng J et al.
Journal of the National Cancer Center, 2021
Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
Wei XW et al.
Thoracic Cancer, 2020
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Robichaux JP et al.
Cancer Cell, 2019
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Ross JS et al.
Cancer, 2018
Select a paper to view details